文献速递肝病

直接抗病毒药物治疗失败后适应性替换的深度测序评估:全长丙型肝炎病毒基因组分析

Fitness-associated substitutions following failure of direct-acting antivirals assessed by deep sequencing of full-length hepatitis C virus genomes.
PubMed 文献 · Aliment Pharmacol Ther · 2020-09-04

研究对8例接受索磷布韦联合NS5A抑制剂治疗失败的基因3a型肝硬化患者,用鸟枪法宏基因组学测序全长HCV基因组,发现治疗失败时除已知NS5A耐药相关替换(尤其Y93H)外,DAA靶区外出现大量氨基酸改变,其中4个位点的改变可提高体外复制能力而不影响NS5A抑制剂敏感性。

要点

  • 治疗失败时除NS5A耐药相关替换外,DAA靶区外出现大量氨基酸改变。
  • 鉴定出4个氨基酸位点,其改变提高体外复制能力而不影响NS5A抑制剂敏感性。
  • 首次在体内观察到并体外证实适应性替换与耐药相关替换同时被选择。

核心结论

  • 首次在基因3a型肝硬化患者索磷布韦-NS5A抑制剂治疗失败时,体内观察到并体外证实表型特征化的适应性替换与耐药相关替换同时被选择。
  • 研究结果可能解释未获得持续病毒学应答的患者治疗后耐药HCV变异株的持续存在。

研究设计与样本

  • 对8例感染基因3a型且伴肝硬化、接受索磷布韦和一种NS5A抑制剂治疗失败的患者,用鸟枪法宏基因组学在治疗开始时和病毒学复发时测序全长HCV基因组。
  • 评估至少在两名患者中选出的DAA靶区外氨基酸改变对体外NS5A抑制剂敏感性和复制能力的影响。

主要发现

  • 治疗失败时,除已知NS5A耐药相关替换(尤其Y93H)被选择外,DAA靶区外观察到大量氨基酸改变。
  • 鉴定出4个氨基酸位点,观察到的改变大幅提高体外复制能力,且不影响NS5A抑制剂敏感性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In hepatitis C virus (HCV) infection, treatment failure is generally associated with the selection of resistance-associated substitutions (RAS) conferring reduced susceptibility to direct-acting antiviral (DAA) drugs. Resistant variants continue to replicate after the end of treatment with potential for transmission. This may result from the selection of "fitness-associated substitutions". AIM: To characterise potential "fitness-associated substitutions" in patients infected with genotype 3a failing DAA drugs METHODS: By means of shotgun metagenomics, we sequenced full-length HCV genomes at treatment initiation and at virological relapse in eight patients infected with genotype 3a with cirrhosis failing sofosbuvir and an NS5A inhibitor. The impact of amino acid changes occurring outside of DAA target regions selected in at least two patients were assessed on the in vitro susceptibility to an NS5A inhibitor and replication capacity. RESULTS: At treatment failure, besides selection of known NS5A RASs, especially Y93H, a large number of amino acid changes was observed outside of DAA target regions. We identified four amino acid positions at which observed changes substantially improved in vitro replication capacity without affecting NS5A inhibitor susceptibility. CONCLUSIONS: This is the first in vivo observation combined with in vitro confirmation of selection of phenotypically characterised "fitness-associated substitutions" together with RASs at the time of sofosbuvir-NS5A inhibitor treatment failure in patients infected with genotype 3a with cirrhosis. Our findings may explain the persistence of resistant HCV variants after treatment in patients who did not achieve sustained virological remission.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Fourati S, Rodriguez C, Soulier A, et al. Fitness-associated substitutions following failure of direct-acting antivirals assessed by deep sequencing of full-length hepatitis C virus genomes. Aliment Pharmacol Ther. 2020. PMID: 32886807. doi:10.1111/apt.16054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。